Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab + domvanalimab + chemotherapy versus pembrolizumab + chemotherapy in first-line metastatic non-small cell lung cancer
2023-509825-38-00Phase 3Authorised
- Sponsor
- Gilead Sciences
- Start
- Dec 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of domvanalimab, zimberelimab, pembrolizumab, pemetrexed, nab-paclitaxel and 3 more in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Overall survival in participants with PD-L1 expression ≥1% tumor cells and Overall survival in all randomized participants. Planned start Dec 2022; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-509825-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509825-38-00.